Zydus Cadila has received the final approval from the US Food & Drug Administration (USFDA) to market Ethacrynate Sodium for Injection USP, 50 mg/vial.

The drug is used to decrease the swelling (edema) caused by various disease conditions such as liver disease, kidney disease, congestive heart failure, cancer etc. and will be produced at the group's formulations manufacturing facility at Moraiya, Ahmedabad.

The group now has more than 165 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.

Shares of the company gained Rs 4, or 0.90%, to trade at Rs 450.35 at the BSE (Monday).